Celecoxib's effect on inflammatory response in patients receiving thoracic and abdominal surgery (Phase II study)

Trial Profile

Celecoxib's effect on inflammatory response in patients receiving thoracic and abdominal surgery (Phase II study)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Inflammation
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2017 Primary endpoint has not been met. (Urine prostaglandin E metabolite at 48 hours following surgery commencement as measured by immunoassay), as per the results published in the Canadian Journal of Anesthesia.
    • 13 Jan 2017 Primary endpoint has not been met. (Plasma prostaglandin E metabolite at 48 hours following surgery commencement as measured by immunoassay), as per the results published in the Canadian Journal of Anesthesia.
    • 13 Jan 2017 Results published in the Canadian Journal of Anesthesia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top